转录调控的miR-26a-5p可能在三阴性乳腺癌中发挥BRCAness作用。

Yue Zhang, Lianqiu Lv, Renjing Zheng, Rong Xie, Yuanhang Yu, Han Liao, Jianying Chen, Bo Zhang
{"title":"转录调控的miR-26a-5p可能在三阴性乳腺癌中发挥BRCAness作用。","authors":"Yue Zhang,&nbsp;Lianqiu Lv,&nbsp;Renjing Zheng,&nbsp;Rong Xie,&nbsp;Yuanhang Yu,&nbsp;Han Liao,&nbsp;Jianying Chen,&nbsp;Bo Zhang","doi":"10.1186/s13058-023-01663-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>DNA damage and DNA damage repair (DDR) are important therapeutic targets for triple-negative breast cancer (TNBC), a subtype with limited chemotherapy efficiency and poor outcome. However, the role of microRNAs in the therapy is emerging. In this study, we explored whether miR-26a-5p could act as BRCAness and enhance chemotherapy sensitivity in TNBC.</p><p><strong>Methods: </strong>Quantitative reverse transcription polymerase chain reaction (RT-qPCR) was used to detect the expression of miR-26a-5p in breast cancer tissues and cell lines. CCK-8 was used to measure drug sensitivity in concentration gradient and time gradient. Comet assay was used to detect DNA damage. Flow cytometry was performed to examine apoptosis. Moreover, we used western blot and immunofluorescence to detect biomarkers. Luciferase reporter assay was performed to verify the combination of miR-26a-5p and 3'UTR of target gene. Hormone deprivation and stimulation assay were used to validate the effect of hormone receptors on the expression of miR-26a-5p. Chromatin immunoprecipitation (ChIP) assays were used to verify the binding sites of ER-a or PR with the promoter of miR-26a-5p. Animal experiments were performed to the effect of miR-26a-5p on Cisplatin treatment.</p><p><strong>Results: </strong>The expression of miR-26a-5p was significantly downregulated in TNBC. Overexpressing miR-26a-5p enhanced the Cisplatin-induced DNA damage and following apoptosis. Interestingly, miR-26a-5p promoted the expression of Fas without Cisplatin stimulating. It suggested that miR-26a-5p provided a hypersensitivity state of death receptor apoptosis and promoted the Cisplatin sensitivity of TNBC cells in vitro and in vivo. Besides, miR-26a-5p negatively regulated the expression of BARD1 and NABP1 and resulted in homologous recombination repair defect (HRD). Notably, overexpressing miR-26a-5p not only facilitated the Olaparib sensitivity of TNBC cells but also the combination of Cisplatin and Olaparib. Furthermore, hormone receptors functioned as transcription factors in the expression of miR-26a-5p, which explained the reasons that miR-26a-5p expressed lowest in TNBC.</p><p><strong>Conclusions: </strong>Taken together, we reveal the important role of miR-26a-5p in Cisplatin sensitivity and highlight its new mechanism in DNA damage and synthetic lethal.</p>","PeriodicalId":9283,"journal":{"name":"Breast Cancer Research : BCR","volume":"25 1","pages":"75"},"PeriodicalIF":0.0000,"publicationDate":"2023-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294332/pdf/","citationCount":"0","resultStr":"{\"title\":\"Transcriptionally regulated miR-26a-5p may act as BRCAness in Triple-Negative Breast Cancer.\",\"authors\":\"Yue Zhang,&nbsp;Lianqiu Lv,&nbsp;Renjing Zheng,&nbsp;Rong Xie,&nbsp;Yuanhang Yu,&nbsp;Han Liao,&nbsp;Jianying Chen,&nbsp;Bo Zhang\",\"doi\":\"10.1186/s13058-023-01663-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>DNA damage and DNA damage repair (DDR) are important therapeutic targets for triple-negative breast cancer (TNBC), a subtype with limited chemotherapy efficiency and poor outcome. However, the role of microRNAs in the therapy is emerging. In this study, we explored whether miR-26a-5p could act as BRCAness and enhance chemotherapy sensitivity in TNBC.</p><p><strong>Methods: </strong>Quantitative reverse transcription polymerase chain reaction (RT-qPCR) was used to detect the expression of miR-26a-5p in breast cancer tissues and cell lines. CCK-8 was used to measure drug sensitivity in concentration gradient and time gradient. Comet assay was used to detect DNA damage. Flow cytometry was performed to examine apoptosis. Moreover, we used western blot and immunofluorescence to detect biomarkers. Luciferase reporter assay was performed to verify the combination of miR-26a-5p and 3'UTR of target gene. Hormone deprivation and stimulation assay were used to validate the effect of hormone receptors on the expression of miR-26a-5p. Chromatin immunoprecipitation (ChIP) assays were used to verify the binding sites of ER-a or PR with the promoter of miR-26a-5p. Animal experiments were performed to the effect of miR-26a-5p on Cisplatin treatment.</p><p><strong>Results: </strong>The expression of miR-26a-5p was significantly downregulated in TNBC. Overexpressing miR-26a-5p enhanced the Cisplatin-induced DNA damage and following apoptosis. Interestingly, miR-26a-5p promoted the expression of Fas without Cisplatin stimulating. It suggested that miR-26a-5p provided a hypersensitivity state of death receptor apoptosis and promoted the Cisplatin sensitivity of TNBC cells in vitro and in vivo. Besides, miR-26a-5p negatively regulated the expression of BARD1 and NABP1 and resulted in homologous recombination repair defect (HRD). Notably, overexpressing miR-26a-5p not only facilitated the Olaparib sensitivity of TNBC cells but also the combination of Cisplatin and Olaparib. Furthermore, hormone receptors functioned as transcription factors in the expression of miR-26a-5p, which explained the reasons that miR-26a-5p expressed lowest in TNBC.</p><p><strong>Conclusions: </strong>Taken together, we reveal the important role of miR-26a-5p in Cisplatin sensitivity and highlight its new mechanism in DNA damage and synthetic lethal.</p>\",\"PeriodicalId\":9283,\"journal\":{\"name\":\"Breast Cancer Research : BCR\",\"volume\":\"25 1\",\"pages\":\"75\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-06-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294332/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast Cancer Research : BCR\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s13058-023-01663-y\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Research : BCR","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s13058-023-01663-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:DNA损伤和DNA损伤修复(DDR)是三阴性乳腺癌(TNBC)的重要治疗靶点,这是一种化疗效率有限且预后较差的亚型。然而,microrna在治疗中的作用正在逐渐显现。在这项研究中,我们探讨了miR-26a-5p是否可以在TNBC中发挥BRCAness作用并增强化疗敏感性。方法:采用定量逆转录聚合酶链反应(RT-qPCR)检测miR-26a-5p在乳腺癌组织和细胞系中的表达。CCK-8在浓度梯度和时间梯度上测定药物敏感性。彗星法检测DNA损伤。流式细胞术检测细胞凋亡。此外,我们使用western blot和免疫荧光检测生物标志物。荧光素酶报告基因实验验证miR-26a-5p与靶基因3'UTR的结合。通过激素剥夺和刺激实验验证激素受体对miR-26a-5p表达的影响。采用染色质免疫沉淀(ChIP)法验证ER-a或PR与miR-26a-5p启动子的结合位点。通过动物实验观察miR-26a-5p对顺铂治疗的影响。结果:miR-26a-5p在TNBC中表达明显下调。过表达miR-26a-5p增强了顺铂诱导的DNA损伤和随后的细胞凋亡。有趣的是,miR-26a-5p在没有顺铂刺激的情况下促进了Fas的表达。提示miR-26a-5p提供了死亡受体凋亡的超敏状态,促进了TNBC细胞体外和体内的顺铂敏感性。此外,miR-26a-5p负调控BARD1和NABP1的表达,导致同源重组修复缺陷(homologous recombination repair defect, HRD)。值得注意的是,过表达miR-26a-5p不仅促进了TNBC细胞对奥拉帕尼的敏感性,也促进了顺铂与奥拉帕尼的联合使用。此外,激素受体在miR-26a-5p的表达中发挥转录因子的作用,这解释了miR-26a-5p在TNBC中表达最低的原因。结论:综上所述,我们揭示了miR-26a-5p在顺铂敏感性中的重要作用,并强调了其在DNA损伤和合成致死中的新机制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Transcriptionally regulated miR-26a-5p may act as BRCAness in Triple-Negative Breast Cancer.

Transcriptionally regulated miR-26a-5p may act as BRCAness in Triple-Negative Breast Cancer.

Transcriptionally regulated miR-26a-5p may act as BRCAness in Triple-Negative Breast Cancer.

Transcriptionally regulated miR-26a-5p may act as BRCAness in Triple-Negative Breast Cancer.

Background: DNA damage and DNA damage repair (DDR) are important therapeutic targets for triple-negative breast cancer (TNBC), a subtype with limited chemotherapy efficiency and poor outcome. However, the role of microRNAs in the therapy is emerging. In this study, we explored whether miR-26a-5p could act as BRCAness and enhance chemotherapy sensitivity in TNBC.

Methods: Quantitative reverse transcription polymerase chain reaction (RT-qPCR) was used to detect the expression of miR-26a-5p in breast cancer tissues and cell lines. CCK-8 was used to measure drug sensitivity in concentration gradient and time gradient. Comet assay was used to detect DNA damage. Flow cytometry was performed to examine apoptosis. Moreover, we used western blot and immunofluorescence to detect biomarkers. Luciferase reporter assay was performed to verify the combination of miR-26a-5p and 3'UTR of target gene. Hormone deprivation and stimulation assay were used to validate the effect of hormone receptors on the expression of miR-26a-5p. Chromatin immunoprecipitation (ChIP) assays were used to verify the binding sites of ER-a or PR with the promoter of miR-26a-5p. Animal experiments were performed to the effect of miR-26a-5p on Cisplatin treatment.

Results: The expression of miR-26a-5p was significantly downregulated in TNBC. Overexpressing miR-26a-5p enhanced the Cisplatin-induced DNA damage and following apoptosis. Interestingly, miR-26a-5p promoted the expression of Fas without Cisplatin stimulating. It suggested that miR-26a-5p provided a hypersensitivity state of death receptor apoptosis and promoted the Cisplatin sensitivity of TNBC cells in vitro and in vivo. Besides, miR-26a-5p negatively regulated the expression of BARD1 and NABP1 and resulted in homologous recombination repair defect (HRD). Notably, overexpressing miR-26a-5p not only facilitated the Olaparib sensitivity of TNBC cells but also the combination of Cisplatin and Olaparib. Furthermore, hormone receptors functioned as transcription factors in the expression of miR-26a-5p, which explained the reasons that miR-26a-5p expressed lowest in TNBC.

Conclusions: Taken together, we reveal the important role of miR-26a-5p in Cisplatin sensitivity and highlight its new mechanism in DNA damage and synthetic lethal.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信